干预代谢危险因素对脑血管病影响的研究进展

doi:10.3969/j.issn.1673-5765.2024.02.002

摘要/Abstract

摘要： 代谢危险因素是脑血管病的重要影响因素。随着代谢性脑血管病概念的提出，如何通过干预代谢危险因素改善此类患者的预后是未来重要的研究方向。代谢危险因素可相互影响并协同作用，降压、调脂、控制血糖等对传统代谢危险因素的干预可有效降低脑血管病的发病率和复发率；抗炎、补充维生素、调节肠道菌群等对残余代谢危险因素的干预同样是影响脑血管病发病及预后的重要措施。新型代谢药物“一专多能”的特点为代谢性脑血管病的治疗和管理提供了新的思路。本综述总结干预代谢危险因素对脑血管病影响的循证医学证据，旨在为代谢性脑血管病的管理提供更多理论支持。

文章导读： 综合管理传统及残余代谢危险因素是代谢性脑血管病治疗的重要方式。

关键词: 代谢性脑血管病；代谢危险因素；胰高血糖素样肽-1受体激动剂

Abstract: Metabolic risk factors play a significant role in the development of cerebrovascular diseases. With the concept of cerebro-metabolic disease proposed, how to improve the prognosis of patients with cerebro-metabolic disease by intervening metabolic risk factors is an important research direction in the future. Metabolic risk factors can interact and act synergistically. Intervention measures for traditional metabolic risk factors such as blood pressure lowering, lipid regulating, and blood glucose controlling can effectively reduce the incidence and recurrence rate of cerebrovascular diseases. Intervention measures for residual metabolic risk factors such as anti-inflammation, vitamin supplements, and regulation of intestinal flora are also key to affecting the incidence and prognosis of cerebrovascular diseases. The characteristics of new metabolic drugs with “one specialization and multiple capabilities” provide new ideas for the treatment and management of cerebro-metabolic disease. This review aims to provide more theoretical support for the management of cerebro-metabolic disease by summarizing evidence from evidence-based medicine on the influence of intervening metabolic risk factors on cerebrovascular diseases.

Key words: Cerebro-metabolic disease; Metabolic risk factor; Glucagon-like peptide-1 receptor agonist

中图分类号:

张方圆, 薛婧, 许杰, 王拥军. 干预代谢危险因素对脑血管病影响的研究进展[J]. 中国卒中杂志, 2024, 19(2): 131-137.

ZHANG Fangyuan, XUE Jing, XU Jie, WANG Yongjun. Research Progress on the Influence of Intervening Metabolic Risk Factors on Cerebrovascular Disease[J]. Chinese Journal of Stroke, 2024, 19(2): 131-137.

参考文献

[1] GBD 2016 Stroke Collaborators. Global，regional，and national burden of stroke，1990—2016：a systematic analysis for the global burden of disease study 2016[J]. Lancet Neurol，2019，18（5）：439-458.
[2] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2020（中文版）（1）[J]. 中国卒中杂志，2022，17（5）：433-447.
WANG Y J，LI Z X，GU H Q，et al. China stroke statistics 2020（1）[J]. Chin J Stroke，2022，17（5）：433-447.
[3] 许杰，王拥军. 代谢性脑血管病：概念、方法、挑战和未来方向[J]. 中国卒中杂志，2023，18（6）：617-627.
XU J，WANG Y J. Cerebro-metabolic disease：concept，method，challenge and future directions[J]. Chin J Stroke，2023，18（6）：617-627.
[4] CORNIER M A，DABELEA D，HERNANDEZ T L，et al. The metabolic syndrome[J]. Endocr Rev，2008，29（7）：777-822.
[5] HE Q，WANG W J，LI H，et al. Genetic insights into the risk of metabolic syndrome and its components on stroke and its subtypes：bidirectional Mendelian randomization[J/OL]. J Cereb Blood Flow Metab，2023，43（2_suppl）：126-137[2023-11-10]. https://doi.org/10.1177/0271678X231169838.
[6] BONORA E，KIECHL S，WILLEIT J，et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome：prospective data from the Bruneck study[J]. Diabetes Care，2003，26（4）：1251-1257.
[7] PARK J H，KWON H M，ROH J K. Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis[J]. Eur J Neurol，2007，14（4）：379-386.
[8] PARK S K，JUNG J Y，OH C M，et al. Components of metabolic syndrome and their relation to the risk of incident cerebral infarction[J]. Endocr J，2021，68（3）：253-259.
[9] LEE E Y，HAN K，KIM D H，et al. Exposure-weighted scoring for metabolic syndrome and the risk of myocardial infarction and stroke：a nationwide population-based study[J/OL]. Cardiovasc Diabetol，2020，19（1）：153[2023-11-10]. https://doi.org/10.1186/s12933-020-01129-x.
[10] KASAI T，MIYAUCHI K，KAJIMOTO K，et al. Relationship between the metabolic syndrome and the incidence of stroke after complete coronary revascularization over a 10-year follow-up period[J]. Atherosclerosis，2009，207（1）：195-199.
[11] CHEN Z L，SU M X，LI Z K，et al. Metabolic syndrome predicts poor outcome in acute ischemic stroke patients after endovascular thrombectomy[J/OL]. Neuropsychiatr Dis Treat，2020，16：2045-2052[2023-11-10]. https://doi.org/10.2147/NDT.S264300.
[12] ZHANG F F，LIU L L，ZHANG C D，et al. Association of metabolic syndrome and its components with risk of stroke recurrence and mortality：a meta-analysis
[J/OL]. Neurology，2021，97（7）：e695-e705[2023-11-10]. https://doi.org/10.1212/WNL.0000000000012415.
[13] SALAS-SALVADÓ J，DÍAZ-LÓPEZ A，RUIZ-CANELA M，et al. Effect of a lifestyle intervention program with energy-restricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors：one-year results of the PREDIMED-Plus trial[J]. Am J Clin Nutr，2019，42（5）：777-788.
[14] WILKINSON M J，MANOOGIAN E N C，ZADOURIAN A，et al. Ten-hour time-restricted eating reduces weight，blood pressure，and atherogenic lipids in patients with metabolic syndrome[J]. Cell Metab，2020，31（1）：92-104. e5.
[15] DEEDWANIA P，MURPHY S，SCHEEN A，et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy：secondary analysis from the FOURIER randomized clinical trial[J]. JAMA Cardiol，2021，6（2）：139-147.
[16] SALTIEL A R，OLEFSKY J M. Inflammatory mechanisms linking obesity and metabolic disease[J]. J Clin Invest，2017，127（1）：1-4.
[17] SILVEIRA ROSSI J L，BARBALHO S M，REVERETE DE ARAUJO R，et al. Metabolic syndrome and cardiovascular diseases：going beyond traditional risk factors[J/OL]. Diabetes Metab Res Rev，2022，38（3）：e3502[2023-11-10]. https://doi.org/10.1002/dmrr.3502.
[18] KELLY P J，LEMMENS R，TSIVGOULIS G. Inflammation and stroke risk：a new target for prevention[J]. Stroke，2021，52（8）：2697-2706.
[19] GEORGAKIS M K，MALIK R，GILL D，et al. Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes：a Mendelian randomization study[J/OL]. Circ Genom Precis Med，2020，13（3）：e002872[2023-11-10]. https://doi.org/10.1161/CIRCGEN.119.002872.
[20] Emerging Risk Factors Collaboration，KAPTOGE S，DI ANGELANTONIO E，et al. C-reactive protein concentration and risk of coronary heart disease，stroke，and mortality：an individual participant meta-analysis[J]. Lancet，2010，375（9709）：132-140.
[21] TORRES S，FABERSANI E，MARQUEZ A，et al. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics[J]. Eur J Nutr，2019，58（1）：27-43.
[22] RIDKER P M，DANIELSON E，FONSECA F A，et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med，2008，359（21）：2195-2207.
[23] RIDKER P M，EVERETT B M，THUREN T，et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med，2017，377（12）：1119-1131.
[24] RIDKER P M，MACFADYEN J G，EVERETT B M，et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab：a secondary analysis from the CANTOS randomised controlled trial[J]. Lancet，2018，391（10118）：319-328.
[25] MARTÍNEZ G J，ROBERTSON S，BARRACLOUGH J，et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome[J/OL]. JAHA，
2015，4（8）：e002128[2023-11-10]. https://doi.org/10.1161/JAHA.115.002128.
[26] CRITTENDEN D B，LEHMANN R A，SCHNECK L，et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout[J]. J Rheumatol，2012，39（7）：1458-1464.
[27] TARDIF J C，KOUZ S，WATERS D D，et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med，2019，381（26）：2497-2505.
[28] NIDORF S M，FIOLET A T L，MOSTERD A，et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med，2020，383（19）：1838-1847.
[29] HSU F C，SIDES E G，MYCHALECKYJ J C，et al. Transcobalamin 2 variant associated with poststroke homocysteine modifies recurrent stroke risk[J]. Neurology，2011，77（16）：1543-1550.
[30] HUANG S M，CAI J R，TIAN Y J. The prognostic value of homocysteine in acute ischemic stroke patients：a systematic review and meta-analysis
[J/OL]. Front Syst Neurosci，2020，14：600582[2023-11-10]. https://doi.org/10.3389/fnsys.2020.600582.
[31] HERRMANN W，HERRMANN M. The controversial role of Hcy and vitamin B deficiency in cardiovascular diseases[J/OL]. Nutrients，2022，14（7）：1412
[2023-11-10]. https://doi.org/10.3390/nu14071412.
[32] MARTÍ-CARVAJAL A J，SOLÀ I，LATHYRIS D，et al. Homocysteine-lowering interventions for preventing cardiovascular events[J/OL]. Cochrane Database Syst Rev，2017，8（8）：CD006612
[2023-11-10]. https://doi.org/10.1002/14651858.CD006612.pub5.
[33] SPENCE J D，YI Q L，HANKEY G J. B vitamins in stroke prevention：time to reconsider[J]. Lancet Neurol，2017，16（9）：750-760.
[34] BJØRKLUND G，PEANA M，DADAR M，et al. The role of B vitamins in stroke prevention[J]. Crit Rev Food Sci Nutr，2022，62（20）：5462-5475.
[35] HUO Y，LI J P，QIN X H，et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China：the CSPPT randomized clinical trial[J]. JAMA，2015，313（13）：1325-1335.
[36] HUANG X，LI Y B，LI P，et al. Association between percent decline in serum total homocysteine and risk of first stroke[J]. Neurology，2017，89（20）：2101-2107.
[37] QIN X H，LI Y B，HE M L，et al. Folic acid therapy reduces serum uric acid in hypertensive patients：a substudy of the China stroke primary prevention trial（CSPPT）[J]. Am J Clin Nutr，2017，105（4）：882-889.
[38] WU H X，ZHANG Y Y，LI H，et al. Interaction of serum calcium and folic acid treatment on first stroke in hypertensive males[J]. Clin Nutr，2021，40（4）：2381-2388.
[39] FLORES-GUERRERO J L，MINOVIC I，GROOTHOF D，et al. Association of plasma concentration of vitamin B12 with all-cause mortality in the general population in the Netherlands[J/OL]. JAMA Netw Open，2020，3（1）：e1919274[2023-11-10].
https://doi.org/10.1001/jamanetworkopen.2019.19274.
[40] AMENT Z，BEVERS M B，WOLCOTT Z，et al. Uric acid and gluconic acid as predictors of hyperglycemia and cytotoxic injury after stroke[J]. Transl Stroke Res，2021，12（2）：293-302.
[41] NARDI V，FRANCHI F，PRASAD M，et al. Uric acid expression in carotid atherosclerotic plaque and serum uric acid are associated with cerebrovascular events[J]. Hypertension，2022，79（8）：1814-1823.
[42] JANSSEN E M，DY S M，MEARA A S，et al. Analysis of patient preferences in lung cancer— estimating acceptable tradeoffs between treatment benefit and side effects[J/OL]. Patient Prefer Adherence，2020，14：927-937[2023-11-10].
https://doi.org/10.2147/PPA.S235430.
[43] SONG M Y，LI N，YAO Y，et al. Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis[J]. J Cell Mol Med，2019，23（8）：4970-4979.
[44] ZHONG C K，ZHONG X Y，XU T，et al. Sex-specific relationship between serum uric acid and risk of stroke：a dose-response meta-analysis of prospective studies
[J/OL]. JAHA，2017，6（4）：e005042[2023-11-10]. https://doi.org/10.1161/JAHA.116.005042.
[45] JUSTICIA C，SALAS-PERDOMO A，PÉREZ-DE-PUIG I，et al. Uric acid is protective after cerebral ischemia/reperfusion in hyperglycemic mice[J]. Transl Stroke Res，2017，8（3）：294-305.
[46] AMARO S，LLULL L，RENÚ A，et al. Uric acid improves glucose-driven oxidative stress in human ischemic stroke[J]. Ann Neurol，2015，77（5）：775-783.
[47] NEMET I，LI X S，HAGHIKIA A，et al. Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality[J]. Eur Heart J，2023，44（32）：3085-3096.
[48] ZHAO L L，WANG C，PENG S X，et al. Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke[J/OL]. J Transl Med，2022，20（1）：459[2023-11-10]. https://doi.org/10.1186/s12967-022-03669-0.
[49] SPYCHALA M S，VENNA V R，JANDZINSKI M，et al. Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome[J]. Ann Neurol，2018，84（1）：23-36.
[50] CHIDAMBARAM S B，RATHIPRIYA A G，MAHALAKSHMI A M，et al. The influence of gut dysbiosis in the pathogenesis and management of ischemic stroke[J/OL]. Cells，2022，11（7）：1239
[2023-11-10]. https://doi.org/10.3390/cells11071239.
[51] AMENT Z，PATKI A，BHAVE V M，et al. Gut microbiota-associated metabolites and risk of ischemic stroke in REGARDS[J]. J Cereb Blood Flow Metab，2023，43（7）：1089-1098.
[52] CHEN R Z，XU Y，WU P，et al. Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota[J/OL]. Pharmacol Res，2019，148：104403[2023-11-10]. https://doi.org/10.1016/j.phrs.2019.104403.
[53] WANG J C，ZHONG Y，ZHU H，et al. Different gender-derived gut microbiota influence stroke outcomes by mitigating inflammation[J/OL]. J Neuroinflammation，2022，19（1）：245[2023-11-10]. https://doi.org/10.1186/s12974-022-02606-8.
[54] PRATLEY R，AMOD A，HOFF S T，et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes（PIONEER 4）：a randomised，double-blind，phase 3a trial[J]. Lancet，2019，394（10192）：39-50.
[55] MARSO S P，BAIN S C，CONSOLI A，et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med，2016，375（19）：1834-1844.
[56] HUSAIN M，BIRKENFELD A L，DONSMARK M，et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med，2019，381（9）：841-851.
[57] HUSAIN M，BAIN S C，JEPPESEN O K，et al. Semaglutide（SUSTAIN and PIONEER）reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk[J]. Diabetes Obes Metab，2020，22（3）：442-451.
[58] STRAIN W D，FRENKEL O，JAMES M A，et al. Effects of semaglutide on stroke subtypes in type 2 diabetes：post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6[J]. Stroke，2022，53（9）：2749-2757.
[59] LINCOFF A M，BROWN-FRANDSEN K，COLHOUN H M，et al. Semaglutide and cardiovascular outcomes in obesity without diabetes[J]. N Engl J Med，2023，389（24），2221-2232.